Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash & Equivalents (2016 - 2025)

Plus Therapeutics has reported Cash & Equivalents over the past 16 years, most recently at $13.1 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 17136.84% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, up 17136.84% year-over-year, with the annual reading at $13.1 million for FY2025, 17136.84% up from the prior year.
  • Cash & Equivalents was $13.1 million for Q4 2025 at Plus Therapeutics, down from $13.3 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $21.3 million in Q3 2021 and troughed at $74000.0 in Q1 2024.
  • The 5-year median for Cash & Equivalents is $12.7 million (2023), against an average of $11.5 million.
  • Year-over-year, Cash & Equivalents plummeted 99.42% in 2024 and then skyrocketed 17136.84% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $21.3 million in 2021, then fell by 14.85% to $18.1 million in 2022, then tumbled by 52.79% to $8.6 million in 2023, then plummeted by 99.11% to $76000.0 in 2024, then skyrocketed by 17136.84% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Cash & Equivalents are $13.1 million (Q4 2025), $13.3 million (Q3 2025), and $2.2 million (Q2 2025).